Canaccord Genuity Keeps Their Buy Rating on Scholar Rock Holding (SRRK)Tip Ranks·2 days ago, 07:45 AMSRRK-1.02%
Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedulebenzinga_article·Aug 10 at 11:03 AMSRRK-1.02%
Scholar Rock: Strengthened Regulatory Path and Cash Position Underscore Attractive Risk‑Reward Ahead of Apitegromab PDUFATip Ranks·Aug 9 at 10:25 PMSRRK-1.02%
Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date | SRRK Stock NewsStockTitan·Aug 7 at 07:20 AMSRRK-1.02%
Scholar Rock (NASDAQ:SRRK) Releases Earnings Results, Meets EstimatesMarket Beat·Aug 6 at 10:26 PMSRRK-1.02%
SRRK: Apitegromab nears FDA approval with strong financials, dual manufacturing, and launch readinessQuartr·Aug 6 at 09:36 AMSRRK-1.02%
Scholar Rock files for up to $200 million at-the-market stock offeringPUBT·Aug 6 at 07:50 AMSRRK-1.02%
Scholar Rock Holding shares are trading higher after the company reported better-than-expected Q2 financial results.benzinga_article·Aug 6 at 07:25 AMSRRK-1.02%
Scholar Rock to present at Canaccord Genuity Annual Growth ConferencePUBT·Jul 29 at 07:00 AMSRRK-1.02%
Scholar Rock Holding Corporation $SRRK Shares Purchased by Redmile Group LLCMarket Beat·Jul 29 at 04:52 AMSRRK-1.02%
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law FirmPR Newswire·Jul 28 at 06:14 PMSRRK-1.02%
Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Average Recommendation of "Buy" by BrokeragesMarket Beat·Jul 26 at 01:14 AMSRRK-1.02%
Scholar Rock (NASDAQ:SRRK) Receives Outperform Rating from WedbushMarket Beat·Jul 21 at 09:18 AMSRRK-1.02%
Scholar Rock announces press release on apitegromab CHMP opinion timing for SMA MAAPUBT·Jul 20 at 07:05 AMSRRK-1.02%
